Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report

A 48-year old woman was diagnosed with metastatic pancreatic acinar cell carcinoma (PACC) and with a marked elevation in alpha-fetoprotein (AFP), this being a recognized but uncommon feature of PACC. As she refused chemotherapy, the combined therapy of lenvatinib and sintilimab (lenvatinib 8 mg, ora...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Lanqun, Shen, Jie, Yang, Yueling, Zou, Zhengyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564141/
https://www.ncbi.nlm.nih.gov/pubmed/34745936
http://dx.doi.org/10.3389/fonc.2021.692480
_version_ 1784593552610689024
author Qin, Lanqun
Shen, Jie
Yang, Yueling
Zou, Zhengyun
author_facet Qin, Lanqun
Shen, Jie
Yang, Yueling
Zou, Zhengyun
author_sort Qin, Lanqun
collection PubMed
description A 48-year old woman was diagnosed with metastatic pancreatic acinar cell carcinoma (PACC) and with a marked elevation in alpha-fetoprotein (AFP), this being a recognized but uncommon feature of PACC. As she refused chemotherapy, the combined therapy of lenvatinib and sintilimab (lenvatinib 8 mg, orally, qd; and sintilimab 100 mg, intravenous glucose tolerance test, q21d) was given, which conferred significant tumor shrinkage and long progression-free survival (>21 months). This study is the first report and description of a PACC demonstrating favorable response to the combination therapy of an antiangiogenic agent and immunotherapy.
format Online
Article
Text
id pubmed-8564141
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85641412021-11-04 Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report Qin, Lanqun Shen, Jie Yang, Yueling Zou, Zhengyun Front Oncol Oncology A 48-year old woman was diagnosed with metastatic pancreatic acinar cell carcinoma (PACC) and with a marked elevation in alpha-fetoprotein (AFP), this being a recognized but uncommon feature of PACC. As she refused chemotherapy, the combined therapy of lenvatinib and sintilimab (lenvatinib 8 mg, orally, qd; and sintilimab 100 mg, intravenous glucose tolerance test, q21d) was given, which conferred significant tumor shrinkage and long progression-free survival (>21 months). This study is the first report and description of a PACC demonstrating favorable response to the combination therapy of an antiangiogenic agent and immunotherapy. Frontiers Media S.A. 2021-10-20 /pmc/articles/PMC8564141/ /pubmed/34745936 http://dx.doi.org/10.3389/fonc.2021.692480 Text en Copyright © 2021 Qin, Shen, Yang and Zou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qin, Lanqun
Shen, Jie
Yang, Yueling
Zou, Zhengyun
Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
title Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
title_full Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
title_fullStr Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
title_full_unstemmed Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
title_short Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
title_sort rapid response to the combination of lenvatinib and sintilimab in a pancreatic acinar cell carcinoma patient with elevated alpha-fetoprotein: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564141/
https://www.ncbi.nlm.nih.gov/pubmed/34745936
http://dx.doi.org/10.3389/fonc.2021.692480
work_keys_str_mv AT qinlanqun rapidresponsetothecombinationoflenvatinibandsintilimabinapancreaticacinarcellcarcinomapatientwithelevatedalphafetoproteinacasereport
AT shenjie rapidresponsetothecombinationoflenvatinibandsintilimabinapancreaticacinarcellcarcinomapatientwithelevatedalphafetoproteinacasereport
AT yangyueling rapidresponsetothecombinationoflenvatinibandsintilimabinapancreaticacinarcellcarcinomapatientwithelevatedalphafetoproteinacasereport
AT zouzhengyun rapidresponsetothecombinationoflenvatinibandsintilimabinapancreaticacinarcellcarcinomapatientwithelevatedalphafetoproteinacasereport

Ejemplares similares